TREX1, a predator for treating MSI-H tumors?

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy has transformed cancer care, but some patients with microsatellite instability-high (MSI-H) tumors do not respond.
• These MSI-H tumors possess high mutation rates and immunogenic potential, yet exhibit immune evasion.

Purpose of the Study:

• To investigate the mechanisms of immune evasion in MSI-H tumors.
• To identify potential therapeutic targets for overcoming immunotherapy resistance in MSI-H cancers.

Main Methods:

• The study focused on the role of the exonuclease TREX1 in regulating cytosolic DNA and immune responses.
• Experiments involved analyzing TREX1's function in degrading cytosolic DNA and its impact on the cGAS-STING pathway.
• Assessed the effects of TREX1 loss on immune cell infiltration and antitumor immunity.

Main Results:

• TREX1 degrades cytosolic DNA, which suppresses the activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway and type I interferon production.
• Loss of TREX1 function restores cytosolic DNA sensing, leading to enhanced immune cell activity.
• TREX1 deficiency promotes the infiltration of CD8+ T cells and NK cells, boosting antitumor immunity.

Conclusions:

• TREX1 is a key mediator of immune evasion in MSI-H tumors by suppressing innate immune sensing.
• Targeting TREX1 presents a promising strategy to enhance the efficacy of immune checkpoint blockade therapy.
• Restoring immune surveillance through TREX1 inhibition could overcome resistance in a subset of cancer patients.